FibroGen (FGEN) has received $62 million in milestone payment from AstraZeneca (AZN). The milestone payment is part of the 2013 collaboration agreement to develop roxadustat (FG-4592) in the U.S. and certain other territories for the treatment of anemia in chronic kidney disease (CKD) patients on or not on dialysis.